Immatics N.V.
IMTX · XNASCIK 1809196fmd_1FJG6BPWFGWJPGTAMKVFE8A82QManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 17 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 34 | 40 | 67 | 88 | 107 | 119 | 148 | 184 |
| Operating income | (34) | (33) | (70) | (86) | 30 | (102) | (39) | (182) |
| Interest expense | 0 | 0 | 10 | (2) | 8 | 7 | 1 | 37 |
| Income before taxes | (32) | (32) | (212) | (93) | 42 | (97) | 21 | (198) |
| Income tax expense | 0 | 0 | 0 | 0 | 14 | (2) | 6 | (2) |
| Net income from continuing operations | (32) | (32) | (212) | (93) | 28 | (95) | 15 | (196) |
| Net income | (31) | (32) | (211) | (93) | 28 | (95) | 15 | (196) |
| Net income to common shareholders | – | – | – | – | 28 | (95) | 15 | (196) |